nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—SLC19A1—tongue—amyotrophic lateral sclerosis	0.0987	0.251	CbGeAlD
Pralatrexate—SLC19A1—Defective AMN causes hereditary megaloblastic anemia 1—TPK1—amyotrophic lateral sclerosis	0.0498	0.114	CbGpPWpGaD
Pralatrexate—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—TPK1—amyotrophic lateral sclerosis	0.0423	0.0966	CbGpPWpGaD
Pralatrexate—DHFR—E2F transcription factor network—UXT—amyotrophic lateral sclerosis	0.0268	0.0613	CbGpPWpGaD
Pralatrexate—TYMS—E2F transcription factor network—UXT—amyotrophic lateral sclerosis	0.0234	0.0535	CbGpPWpGaD
Pralatrexate—SLC19A1—nervous system—amyotrophic lateral sclerosis	0.0227	0.0578	CbGeAlD
Pralatrexate—SLC19A1—central nervous system—amyotrophic lateral sclerosis	0.0219	0.0556	CbGeAlD
Pralatrexate—SLC19A1—cerebellum—amyotrophic lateral sclerosis	0.0214	0.0543	CbGeAlD
Pralatrexate—DHFR—embryo—amyotrophic lateral sclerosis	0.0205	0.052	CbGeAlD
Pralatrexate—FPGS—medulla oblongata—amyotrophic lateral sclerosis	0.0201	0.0512	CbGeAlD
Pralatrexate—FPGS—spinal cord—amyotrophic lateral sclerosis	0.018	0.0457	CbGeAlD
Pralatrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—TPK1—amyotrophic lateral sclerosis	0.0177	0.0403	CbGpPWpGaD
Pralatrexate—SLC19A1—brain—amyotrophic lateral sclerosis	0.0174	0.0441	CbGeAlD
Pralatrexate—FPGS—nervous system—amyotrophic lateral sclerosis	0.0151	0.0385	CbGeAlD
Pralatrexate—FPGS—central nervous system—amyotrophic lateral sclerosis	0.0146	0.037	CbGeAlD
Pralatrexate—FPGS—cerebellum—amyotrophic lateral sclerosis	0.0142	0.0362	CbGeAlD
Pralatrexate—SLC19A1—Folate Metabolism—SOD1—amyotrophic lateral sclerosis	0.0142	0.0324	CbGpPWpGaD
Pralatrexate—DHFR—medulla oblongata—amyotrophic lateral sclerosis	0.0131	0.0333	CbGeAlD
Pralatrexate—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.0129	0.0767	CcSEcCtD
Pralatrexate—DHFR—spinal cord—amyotrophic lateral sclerosis	0.0117	0.0297	CbGeAlD
Pralatrexate—FPGS—brain—amyotrophic lateral sclerosis	0.0116	0.0294	CbGeAlD
Pralatrexate—TYMS—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.0104	0.0238	CbGpPWpGaD
Pralatrexate—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0597	CcSEcCtD
Pralatrexate—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00998	0.0592	CcSEcCtD
Pralatrexate—TYMS—nervous system—amyotrophic lateral sclerosis	0.00993	0.0252	CbGeAlD
Pralatrexate—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00984	0.0584	CcSEcCtD
Pralatrexate—DHFR—nervous system—amyotrophic lateral sclerosis	0.00983	0.025	CbGeAlD
Pralatrexate—TYMS—central nervous system—amyotrophic lateral sclerosis	0.00956	0.0243	CbGeAlD
Pralatrexate—DHFR—central nervous system—amyotrophic lateral sclerosis	0.00947	0.0241	CbGeAlD
Pralatrexate—TYMS—cerebellum—amyotrophic lateral sclerosis	0.00934	0.0238	CbGeAlD
Pralatrexate—DHFR—cerebellum—amyotrophic lateral sclerosis	0.00925	0.0235	CbGeAlD
Pralatrexate—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00887	0.0527	CcSEcCtD
Pralatrexate—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00874	0.0518	CcSEcCtD
Pralatrexate—TYMS—Nucleotide metabolism—GSR—amyotrophic lateral sclerosis	0.00851	0.0194	CbGpPWpGaD
Pralatrexate—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00786	0.0466	CcSEcCtD
Pralatrexate—TYMS—brain—amyotrophic lateral sclerosis	0.00759	0.0193	CbGeAlD
Pralatrexate—DHFR—brain—amyotrophic lateral sclerosis	0.00752	0.0191	CbGeAlD
Pralatrexate—FPGS—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.00632	0.0144	CbGpPWpGaD
Pralatrexate—Back pain—Riluzole—amyotrophic lateral sclerosis	0.0063	0.0374	CcSEcCtD
Pralatrexate—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00602	0.0357	CcSEcCtD
Pralatrexate—SLC19A1—Disease—TPK1—amyotrophic lateral sclerosis	0.00589	0.0134	CbGpPWpGaD
Pralatrexate—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00583	0.0346	CcSEcCtD
Pralatrexate—SLC19A1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—amyotrophic lateral sclerosis	0.00575	0.0131	CbGpPWpGaD
Pralatrexate—Cough—Riluzole—amyotrophic lateral sclerosis	0.00568	0.0337	CcSEcCtD
Pralatrexate—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00531	0.0315	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.0053	0.0121	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.0052	0.0309	CcSEcCtD
Pralatrexate—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00519	0.0308	CcSEcCtD
Pralatrexate—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00506	0.0301	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—SOD1—amyotrophic lateral sclerosis	0.00504	0.0115	CbGpPWpGaD
Pralatrexate—FPGS—Disease—TPK1—amyotrophic lateral sclerosis	0.00501	0.0114	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00493	0.0113	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00493	0.0113	CbGpPWpGaD
Pralatrexate—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—amyotrophic lateral sclerosis	0.00489	0.0112	CbGpPWpGaD
Pralatrexate—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00474	0.0281	CcSEcCtD
Pralatrexate—SLC19A1—Disease—VTA1—amyotrophic lateral sclerosis	0.00471	0.0108	CbGpPWpGaD
Pralatrexate—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00462	0.0274	CcSEcCtD
Pralatrexate—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00458	0.0272	CcSEcCtD
Pralatrexate—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00454	0.027	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00451	0.0103	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00434	0.0258	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.00432	0.00986	CbGpPWpGaD
Pralatrexate—SLC19A1—Folate Metabolism—TP53—amyotrophic lateral sclerosis	0.00427	0.00975	CbGpPWpGaD
Pralatrexate—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.0042	0.0249	CcSEcCtD
Pralatrexate—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.0042	0.0249	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00419	0.00958	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00419	0.00958	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00419	0.00958	CbGpPWpGaD
Pralatrexate—FPGS—Disease—VTA1—amyotrophic lateral sclerosis	0.004	0.00914	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00394	0.009	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—VAPA—amyotrophic lateral sclerosis	0.00384	0.00876	CbGpPWpGaD
Pralatrexate—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00381	0.0226	CcSEcCtD
Pralatrexate—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00376	0.0223	CcSEcCtD
Pralatrexate—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00364	0.0216	CcSEcCtD
Pralatrexate—SLC19A1—Disease—CHMP2B—amyotrophic lateral sclerosis	0.00357	0.00815	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00357	0.00814	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—DAO—amyotrophic lateral sclerosis	0.00357	0.00814	CbGpPWpGaD
Pralatrexate—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00338	0.02	CcSEcCtD
Pralatrexate—FPGS—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00335	0.00766	CbGpPWpGaD
Pralatrexate—Rash—Riluzole—amyotrophic lateral sclerosis	0.00335	0.0199	CcSEcCtD
Pralatrexate—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00335	0.0199	CcSEcCtD
Pralatrexate—SLC19A1—Disease—PLB1—amyotrophic lateral sclerosis	0.00323	0.00737	CbGpPWpGaD
Pralatrexate—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00316	0.0187	CcSEcCtD
Pralatrexate—FPGS—Disease—CHMP2B—amyotrophic lateral sclerosis	0.00303	0.00693	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—DAO—amyotrophic lateral sclerosis	0.00303	0.00692	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.00297	0.00678	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.00288	0.00658	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—VCP—amyotrophic lateral sclerosis	0.00288	0.00657	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.00277	0.00632	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PLB1—amyotrophic lateral sclerosis	0.00274	0.00626	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.00271	0.00619	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.0027	0.00617	CbGpPWpGaD
Pralatrexate—DHFR—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.00264	0.00603	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—GSR—amyotrophic lateral sclerosis	0.00249	0.00569	CbGpPWpGaD
Pralatrexate—FPGS—Disease—VCP—amyotrophic lateral sclerosis	0.00245	0.00558	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—TUBA4A—amyotrophic lateral sclerosis	0.0024	0.00547	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—OPTN—amyotrophic lateral sclerosis	0.0024	0.00547	CbGpPWpGaD
Pralatrexate—TYMS—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.0023	0.00526	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PLB1—amyotrophic lateral sclerosis	0.0023	0.00525	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—OPTN—amyotrophic lateral sclerosis	0.00214	0.00489	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TUBA4A—amyotrophic lateral sclerosis	0.00214	0.00489	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—GSR—amyotrophic lateral sclerosis	0.00212	0.00484	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.0021	0.00478	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TPK1—amyotrophic lateral sclerosis	0.00209	0.00478	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—OPTN—amyotrophic lateral sclerosis	0.00209	0.00477	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—TUBA4A—amyotrophic lateral sclerosis	0.00209	0.00477	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CST3—amyotrophic lateral sclerosis	0.00206	0.00471	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—CHAT—amyotrophic lateral sclerosis	0.00205	0.00468	CbGpPWpGaD
Pralatrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—amyotrophic lateral sclerosis	0.00204	0.00467	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—DCTN1—amyotrophic lateral sclerosis	0.00204	0.00465	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TUBA4A—amyotrophic lateral sclerosis	0.00187	0.00427	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—OPTN—amyotrophic lateral sclerosis	0.00187	0.00427	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—DCTN1—amyotrophic lateral sclerosis	0.00182	0.00416	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—DCTN1—amyotrophic lateral sclerosis	0.00178	0.00406	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.00177	0.00403	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CST3—amyotrophic lateral sclerosis	0.00176	0.00401	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00175	0.004	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00175	0.004	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CHAT—amyotrophic lateral sclerosis	0.00174	0.00398	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.00169	0.00385	CbGpPWpGaD
Pralatrexate—DHFR—Disease—VTA1—amyotrophic lateral sclerosis	0.00167	0.00382	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—VAPA—amyotrophic lateral sclerosis	0.0016	0.00366	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—DCTN1—amyotrophic lateral sclerosis	0.00159	0.00363	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00153	0.00349	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00153	0.00349	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—TP53—amyotrophic lateral sclerosis	0.00152	0.00346	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CASP9—amyotrophic lateral sclerosis	0.0015	0.00343	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00149	0.0034	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—FIG4—amyotrophic lateral sclerosis	0.0014	0.0032	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—VAPA—amyotrophic lateral sclerosis	0.0014	0.00319	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.0013	0.00297	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ERBB4—amyotrophic lateral sclerosis	0.00128	0.00293	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CASP9—amyotrophic lateral sclerosis	0.00128	0.00291	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CHMP2B—amyotrophic lateral sclerosis	0.00127	0.00289	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—DAO—amyotrophic lateral sclerosis	0.00127	0.00289	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00122	0.00279	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—amyotrophic lateral sclerosis	0.00122	0.00278	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PLB1—amyotrophic lateral sclerosis	0.00115	0.00262	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.00115	0.00262	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—DAO—amyotrophic lateral sclerosis	0.00111	0.00252	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.0011	0.00251	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ERBB4—amyotrophic lateral sclerosis	0.00109	0.00249	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—amyotrophic lateral sclerosis	0.00106	0.00242	CbGpPWpGaD
Pralatrexate—DHFR—Disease—VCP—amyotrophic lateral sclerosis	0.00102	0.00233	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.00101	0.00231	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—APOE—amyotrophic lateral sclerosis	0.000994	0.00227	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00096	0.00219	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000951	0.00217	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000936	0.00214	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSR—amyotrophic lateral sclerosis	0.000886	0.00202	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000882	0.00201	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.00086	0.00196	CbGpPWpGaD
Pralatrexate—FPGS—Disease—APOE—amyotrophic lateral sclerosis	0.000845	0.00193	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000838	0.00191	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—APOE—amyotrophic lateral sclerosis	0.000832	0.0019	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSR—amyotrophic lateral sclerosis	0.000773	0.00176	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000749	0.00171	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CST3—amyotrophic lateral sclerosis	0.000733	0.00167	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000728	0.00166	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—APOE—amyotrophic lateral sclerosis	0.000708	0.00162	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTGS2—amyotrophic lateral sclerosis	0.000681	0.00155	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000635	0.00145	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTGS2—amyotrophic lateral sclerosis	0.000579	0.00132	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.00057	0.0013	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000566	0.00129	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	0.000543	0.00124	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CASP9—amyotrophic lateral sclerosis	0.000533	0.00122	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000485	0.00111	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ERBB4—amyotrophic lateral sclerosis	0.000456	0.00104	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000391	0.000893	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000359	0.00082	CbGpPWpGaD
Pralatrexate—DHFR—Disease—APOE—amyotrophic lateral sclerosis	0.000353	0.000806	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000341	0.000779	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000314	0.000716	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—APOE—amyotrophic lateral sclerosis	0.000296	0.000675	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—amyotrophic lateral sclerosis	0.000281	0.000641	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—APOE—amyotrophic lateral sclerosis	0.000258	0.000589	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—amyotrophic lateral sclerosis	0.000245	0.000559	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTGS2—amyotrophic lateral sclerosis	0.000242	0.000552	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000203	0.000462	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000177	0.000404	CbGpPWpGaD
